Trial Information
A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)
Inclusion Criteria:
- Diagnosis of multiple myeloma.
- Received at least one prior systemic therapy other than single-agent corticosteroids.
- Measurable disease of monoclonal protein greater than or equal to 0.5 gram/dL in
plasma or 0.5 gram/24 hr urine collection, or greater than 10 mg/dL free light chain
(FLC) in serum as determined by serum FLC assay and provided the serum FLC ratio is
abnormal.
Exclusion Criteria:
- Received an allogenic stem cell transplant.
- Previous intolerance of lenalidomide or dexamethasone.
- Primary invasive malignancy (other than multiple myeloma) within the last 3 years.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Adverse events and lab abnormalities.
Outcome Time Frame:
Within 3 weeks of final infusion of SGN-40
Safety Issue:
Yes
Principal Investigator
Nancy Whiting, PharmD
Investigator Role:
Study Director
Investigator Affiliation:
Seattle Genetics, Inc.
Authority:
United States: Food and Drug Administration
Study ID:
SG040-0006
NCT ID:
NCT00525447
Start Date:
August 2007
Completion Date:
February 2010
Related Keywords:
- Multiple Myeloma
- Antigens, CD40
- Antibodies, Monoclonal
- Combined Modality Therapy
- Multiple Myeloma
- Blood Coagulation Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Immunoproliferative Disorders
- Lymphoproliferative Disorders
- Paraproteinemias
- Vascular Diseases
- Antibody-Dependent Cell Cytotoxicity
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
Barbara Ann Karmanos Cancer Institute |
Detroit, Michigan 48201 |
Avera Cancer Institute |
Sioux Falls, South Dakota 57105 |
Hackensack University Medical Center |
Hackensack, New Jersey 07601 |
Weill Medical College of Cornell University |
New York, New York 10021 |
Rocky Mountain Cancer Center |
Denver, Colorado 80218 |
Baylor University Medical Center |
Dallas, Texas 75246 |
Nebraska Methodist Hospital |
Omaha, Nebraska 68114 |
H. Lee Moffitt Cancer Center & Research Institute |
Tampa, Florida 33612 |
Dana Farber Cancer Institute |
Boston, Massachusetts 02115 |